Tuesday, 20 Aug 2019

You are here

AURA-LV Trial - Voclosporin Effective in Lupus Nephritis

The AURA-LV trial assessed voclosporin, a calcineurin inhibitor in patients with active lupus nephritis (LN) and found that low-dose voclosporin may be successfully added to mycophenolate mofetil and corticosteroids to controll active LN.

A total of 265 lupus nephritis patients were enrolled from 79 worldwide centers in this Phase 2, randomized, double-blind, placebo-controlled trial of two doses of voclosporin (23.7 mg or 39.5 mg, given twice daily) versus placebo in patients already taking mycophenolate and steroids.  The primary endpoint was CRR at 24 weeks; the secondary endpoint was CRR at 48 weeks.

By week 24, a complete renal response (CRR) was achieved in 27-32% on voclosporin and 19% in the placebo group.  A significantly higher CRR rate was seen in the low-dose voclosporin group out to 48 weeks.

Serious adverse events were higher in the voclosporin and more deaths in the low-dose group compared to placebo and high-dose voclosporin groups.

These data sugggest the efficacy of low dose voclosporin in LN but adverse events may limit its ultimate fate.

More trials are in progress.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.